MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR ITRACONAZOLE

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [1 ]
Kueenburg, Elisabeth [1 ]
机构：
[1] Priothera SAS, St Louis, France
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P768
引用
收藏
页码：740 / 741
页数：2
相关论文
共 50 条
  • [41] IMPACT OF THE DRUG-DRUG INTERACTION DATABASE SFINX ON THE PREVALENCE OF CLINICALLY RELEVANT DRUG INTERACTIONS
    Andersson, M. L.
    Eiermann, B.
    Wettermark, B.
    Bottiger, Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 138 - 138
  • [42] Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions
    Garcia, Luna Prieto
    Janzen, David
    Kanebratt, Kajsa P.
    Ericsson, Hans
    Lennernas, Hans
    Lundahl, Anna
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (10) : 1420 - 1433
  • [43] Fluorescent probes for rapid screening of potential drug-drug interactions at the CYP3A4 level
    Chougnet, Antoinette
    Grinkova, Yelena
    Ricard, David
    Sligar, Stephen
    Woggon, Wolf-D.
    CHEMMEDCHEM, 2007, 2 (05) : 717 - 724
  • [44] Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase® and hypothesis on the underlying mechanism
    Delafoy, Clemence
    Dolladille, Charles
    Besnier, Paul
    Sassier, Marion
    Bourgine, Joanna
    Lelong-Boulouard, Veronique
    Alexandre, Joachim
    Guillaume, Cyril
    Fedrizzi, Sophie
    Chretien, Basile
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (07) : 1049 - 1051
  • [45] Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase® and hypothesis on the underlying mechanism
    Clémence Delafoy
    Charles Dolladille
    Paul Besnier
    Marion Sassier
    Joanna Bourgine
    Véronique Lelong-Boulouard
    Joachim Alexandre
    Cyril Guillaume
    Sophie Fedrizzi
    Basile Chrétien
    European Journal of Clinical Pharmacology, 2020, 76 : 1049 - 1051
  • [46] Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
    Kari T. Kivistö
    Jun-Sheng Wang
    Janne T. Backman
    Leena Nyman
    Päivi Taavitsainen
    Markku Anttila
    Pertti J. Neuvonen
    European Journal of Clinical Pharmacology, 2001, 57 : 37 - 42
  • [47] Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development
    Sinz, Michael W.
    DRUG METABOLISM REVIEWS, 2013, 45 (01) : 3 - 14
  • [48] Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
    Kivistö, KT
    Wang, JS
    Backman, JT
    Nyman, L
    Taavitsainen, P
    Anttila, M
    Neuvonen, PJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) : 37 - 42
  • [49] Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4
    Jiang, Pin
    Chen, Tao
    Chu, Lin-Feng
    Xu, Ren-Peng
    Gao, Jin-Ting
    Wang, Li
    Liu, Qiang
    Tang, Lily
    Wan, Hong
    Li, Ming
    Ren, Hong-Can
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (10) : 721 - 731
  • [50] Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions
    Ly, Justin Q.
    Messick, Kirsten
    Qin, Ann
    Takahashi, Ryan H.
    Choo, Edna F.
    MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1754 - 1759
12345